Bispecific Antibodies for Multiple Myeloma: Recent Advancements and Strategies for Increasing Their Efficacy

被引：1
作者：
Wang, Moran [1 ]
Wang, Chaofan [1 ]
Deng, Jun [1 ]
Wang, Huafang [1 ]
Sun, Chunyan [1 ]
Luo, Shanshan [1 ]
Hu, Yu [1 ]
机构：
[1] Huazhong Univ Sci & Technol, Union Hosp, Inst Hematol, Tongji Med Coll, Wuhan 430022, Hubei, Peoples R China
来源：
FRONTIERS IN BIOSCIENCE-LANDMARK | 2024年 / 29卷 / 06期
关键词：
bispecific antibodies; multiple myeloma; immunotherapy; tumor antigens; resistance mechanism; CELL MATURATION ANTIGEN; BONE-MARROW MICROENVIRONMENT; T-CELLS; REDIRECTING ANTIBODY; PLASMA-CELLS; B7-H1; PD-L1; RECEPTOR; BCMA; EXPRESSION; PROTEIN;
D O I：
10.31083/j.fbl2906216
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
The treatment options for multiple myeloma (MM) have undergone significant transformation with the advent of immunotherapy. Novel therapies that focus on tumor antigens now drive advances in MM research. Bispecific antibodies (bsAbs) leverage revolutionary advances in bioengineering techniques and embody the second generation of antibody-based tumor therapy. Recent studies on bsAbs in relapsed/refractory MM cases have revealed remarkable efficacy and acceptable safety profiles. The approval of elranatamab and teclistamab represents the next step in the development of bsAbs for the treatment of MM. This review article addresses the antigen targeting, efficacy, safety, and strategies in the application of bsAbs against treatment-resistant MM, with a focus on clinical trials and real-world data.
引用
收藏
页数：18
相关论文
共 174 条
  • [1] Real-World Evaluation of Teclistamab for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM)
    Asoori, Sireesha
    Popat, Rakesh
    Martinez-Lopez, Joaquin
    Kastritis, Efstathios
    Brunaldi, Larissa
    Bansal, Radhika
    Corraes, Andre De Menezes Silva
    Yong, Kwee
    Mactier, Catriona
    Corona, Magdalena
    Saez Marin, Adolfo Jesus
    Fotiou, Despina
    Dimopoulos, Meletios Athanasios
    Chhabra, Saurabh
    Ailawadhi, Sikander
    Parrondo, Ricardo
    Martin, Thomas
    Durie, Brian G. M.
    Lin, Yi
    [J]. BLOOD, 2023, 142
  • [2] Overexpression of G protein-coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myeloma
    Atamaniuk, Johanna
    Gleiss, Andreas
    Porpaczy, Edit
    Kainz, Birgit
    Grunt, Thomas W.
    Raderer, Markus
    Hilgarth, Bernadette
    Drach, Johannes
    Ludwig, Heinz
    Gisslinger, Heinz
    Jaeger, Ulrich
    Gaiger, Alexander
    [J]. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2012, 42 (09) : 953 - 960
  • [3] Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma
    Atanackovic, D.
    Luetkens, T.
    Kroeger, N.
    [J]. LEUKEMIA, 2014, 28 (05) : 993 - 1000
  • [4] Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial
    Bahlis, Nizar J.
    Costello, Caitlin L.
    Raje, Noopur S.
    Levy, Moshe Y.
    Dholaria, Bhagirathbhai
    Solh, Melhem
    Tomasson, Michael H.
    Damore, Michael A.
    Jiang, Sibo
    Basu, Cynthia
    Skoura, Athanasia
    Chan, Edward M.
    Trudel, Suzanne
    Jakubowiak, Andrzej
    Gasparetto, Cristina
    Chu, Michael P.
    Dalovisio, Andrew
    Sebag, Michael
    Lesokhin, Alexander M.
    [J]. NATURE MEDICINE, 2023, 29 (10) : 2570 - +
  • [5] Bar N, 2023, Blood, V142, P2011
  • [6] Syndecan-1 (CD138) Suppresses Apoptosis in Multiple Myeloma by Activating IGF1 Receptor: Prevention by SynstatinIGF1R Inhibits Tumor Growth
    Beauvais, DeannaLee M.
    Jung, Oisun
    Yang, Yang
    Sanderson, Ralph D.
    Rapraeger, Alan C.
    [J]. CANCER RESEARCH, 2016, 76 (17) : 4981 - 4993
  • [7] Syndecans in tumor cell adhesion and signaling
    Beauvais D.M.
    Rapraeger A.C.
    [J]. Reproductive Biology and Endocrinology, 2 (1)
  • [8] Strategies and challenges for the next generation of antibody drug conjugates
    Beck, Alain
    Goetsch, Liliane
    Dumontet, Charles
    Corvaia, Nathalie
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2017, 16 (05) : 315 - 337
  • [9] Cytokines in clinical cancer immunotherapy
    Berraondo, Pedro
    Sanmamed, Miguel F.
    Ochoa, Maria C.
    Etxeberria, Inaki
    Aznar, Maria A.
    Luis Perez-Gracia, Jose
    Rodriguez-Ruiz, Maria E.
    Ponz-Sarvise, Mariano
    Castanon, Eduardo
    Melero, Ignacio
    [J]. BRITISH JOURNAL OF CANCER, 2019, 120 (01) : 6 - 15
  • [10] Pathogenesis beyond the cancer clone(s) in multiple myeloma
    Bianchi, Giada
    Munshi, Nikhil C.
    [J]. BLOOD, 2015, 125 (20) : 3049 - 3058
12345678910